Guggenheim initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $15 price target The company’s lead asset, SAB-142, is in pivotal development for Stage 3 Type 1 Diabetes, where no disease-modifying therapy is currently approved, the analyst tells investors. The firm expects positive pivotal SafeGUARD data in T1D in the second half of 2027 and estimates about $2B in peak global sales for SAB-142 in Stage 3 T1D if approved, the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial
- SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint
- Eleven new option listings and two option delistings on December 8th
- SAB Biotherapeutics to present data on progress in development of SAB-142
- SAB Biotherapeutics Reports Positive Q3 2025 Earnings